GID-MT565 Optilume for recurrent bulbar urethral strictures: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 12 July 2022.
Search results
254 results
-
-
GID-MT564 GreenLight XPS for treating benign prostatic hyperplasia: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 13 July 2022.
-
Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223
Awaiting development [GID-HST10019] Expected publication date: TBC
-
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Awaiting development [GID-HST10049] Expected publication date: TBC
-
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]
Awaiting development [GID-HST10022] Expected publication date: TBC
-
Lonafarnib for treating progeria and progeroid laminopathies [ID3867]
Awaiting development [GID-HST10039] Expected publication date: TBC
-
VTS-270 for treating Niemann-Pick type C1 (ID1267)
Awaiting development [GID-HST10020] Expected publication date: TBC
-
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]
Awaiting development [GID-HST10032] Expected publication date: TBC
-
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]
Awaiting development [GID-HST10046] Expected publication date: TBC
-
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 30 June 2022.
-
YAG laser vitreolysis for symptomatic vitreous floaters: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 30 June 2022.
-
Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules: interventional procedure consultation
We are listening to your views on this Interventional procedures guidance. Comments close 30 June 2022.
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2022.
-
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis [ID3787]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 12 July 2022.
-
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 14 July 2022.
-
Balloon disimpaction of fetal head at emergency caesarean delivery
Awaiting development [GID-IPG10220] Expected publication date: 16 November 2022
-
Carotid artery stent placement for asymptomatic extracranial carotid stenosis
Awaiting development [GID-IPG10250] Expected publication date: 25 October 2023
-
Cryotherapy for Chronic Rhinitis
Awaiting development [GID-IPG10251] Expected publication date: 27 September 2023
-
Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia
Awaiting development [GID-IPG10249] Expected publication date: 27 September 2023
-
Radiofrequency denervation for osteoarthritic knee pain
Awaiting development [GID-IPG10236] Expected publication date: 29 June 2023
-
Endoscopic ultrasound-guided gallbladder drainage for acute cholecystitis
Awaiting development [GID-IPG10235] Expected publication date: 28 June 2023
-
Endoscopic ultrasound guided biliary drainage for malignant obstruction
Awaiting development [GID-IPG10234] Expected publication date: 21 April 2023
-
Insertion of neo-chordae into the beating heart for mitral regurgitation
Awaiting development [GID-IPG10216] Expected publication date: 21 April 2023
-
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancer
Awaiting development [GID-IPG10261] Expected publication date: TBC
-
Irreversible electroporation for treating prostate cancer
Awaiting development [GID-IPG10262] Expected publication date: 01 February 2023
-
Vaginal natural orifice transluminal endoscopic surgery for hysterectomy and adnexal surgery
Awaiting development [GID-IPG10240] Expected publication date: 23 August 2023
-
Targeted temperature management following cardiac arrest to improve neurological
Awaiting development [GID-IPG10238] Expected publication date: 25 May 2023
-
Aortic valve reconstruction with glutaraldehyde-treated autologous pericardium
Awaiting development [GID-IPG10237] Expected publication date: 23 August 2023
-
Electrosurgery (diathermy and coblation) for tonsillectomy
Awaiting development [GID-IPG10246] Expected publication date: 26 July 2023
-
Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosis
Awaiting development [GID-IPG10247] Expected publication date: TBC
-
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by high spinal cord injuries
Awaiting development [GID-IPG10248] Expected publication date: 22 May 2023
-
Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine
Awaiting development [GID-IPG10175] Expected publication date: 19 October 2022
-
Biodegradable subacromial spacer insertion for rotator cuff tears
Awaiting development [GID-IPG10264] Expected publication date: 25 October 2023
-
Selective internal radiation therapy for unresectable colorectal metastases in the liver
Awaiting development [GID-IPG10252] Expected publication date: 29 November 2023
-
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
Awaiting development [GID-IPG10205] Expected publication date: 17 August 2022
-
Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]
Awaiting development [GID-TA11000] Expected publication date: TBC
-
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]
Awaiting development [GID-TA10972] Expected publication date: TBC
-
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]
Awaiting development [GID-TA11013] Expected publication date: TBC
-
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer [ID5110]
Awaiting development [GID-TA11023] Expected publication date: TBC
-
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]
Awaiting development [GID-TA11018] Expected publication date: TBC
-
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]
Awaiting development [GID-TA11017] Expected publication date: TBC
-
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]
Awaiting development [GID-TA10960] Expected publication date: TBC
-
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]
Awaiting development [GID-TA10969] Expected publication date: TBC
-
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5073]
Awaiting development [GID-TA10959] Expected publication date: TBC
-
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID 5096]
Awaiting development [GID-TA11007] Expected publication date: TBC
-
Teclistamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5087]
Awaiting development [GID-TA10968] Expected publication date: TBC
-
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]
Awaiting development [GID-TA10967] Expected publication date: TBC